Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Has Consensus Target Price of $8.17

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given a consensus recommendation of “Hold” by the seven brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $7.33.

JSPR has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Wall Street Zen cut shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, Piper Sandler started coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price objective for the company.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $0.59 on Friday. The firm has a market capitalization of $19.48 million, a price-to-earnings ratio of -0.37 and a beta of 3.04. Jasper Therapeutics has a one year low of $0.32 and a one year high of $2.69. The business has a 50-day simple moving average of $0.70 and a 200 day simple moving average of $0.76.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. On average, sell-side analysts expect that Jasper Therapeutics will post -1.14 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity.